Denali Therapeutics (NASDAQ:DNLI) Price Target Raised to $87.00 at HC Wainwright

Denali Therapeutics (NASDAQ:DNLI) had its price objective increased by equities researchers at HC Wainwright from $80.00 to $87.00 in a report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 367.74% from the company’s previous close.

DNLI has been the subject of a number of other research reports. Stifel Nicolaus upgraded Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price objective for the company in a research report on Monday, December 16th. JPMorgan Chase & Co. reduced their target price on Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating for the company in a research report on Tuesday, January 7th. The Goldman Sachs Group decreased their price target on shares of Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Baird R W upgraded shares of Denali Therapeutics to a “strong-buy” rating in a research note on Tuesday, January 7th. Finally, Jefferies Financial Group lifted their target price on shares of Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Two equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.42.

Denali Therapeutics Trading Down 1.5 %

Shares of NASDAQ:DNLI opened at $18.60 on Friday. The stock has a market capitalization of $2.68 billion, a PE ratio of -6.74 and a beta of 1.43. Denali Therapeutics has a 1 year low of $14.56 and a 1 year high of $33.33. The firm has a fifty day moving average price of $21.44 and a 200 day moving average price of $24.63.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.08. On average, sell-side analysts forecast that Denali Therapeutics will post -2.71 earnings per share for the current fiscal year.

Insider Transactions at Denali Therapeutics

In related news, insider Carole Ho sold 12,255 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $20.22, for a total transaction of $247,796.10. Following the transaction, the insider now owns 178,580 shares in the company, valued at $3,610,887.60. This represents a 6.42 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Vicki L. Sato sold 3,080 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $20.91, for a total transaction of $64,402.80. Following the completion of the sale, the director now owns 107,976 shares of the company’s stock, valued at $2,257,778.16. The trade was a 2.77 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 47,940 shares of company stock valued at $973,442 in the last three months. 7.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. FMR LLC lifted its position in Denali Therapeutics by 3,234.3% during the 3rd quarter. FMR LLC now owns 7,831,378 shares of the company’s stock valued at $228,128,000 after purchasing an additional 7,596,508 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Denali Therapeutics by 63.2% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,749,486 shares of the company’s stock worth $109,223,000 after buying an additional 1,451,770 shares during the last quarter. Norges Bank acquired a new position in Denali Therapeutics in the fourth quarter valued at approximately $21,717,000. Wellington Management Group LLP boosted its stake in Denali Therapeutics by 9.2% in the third quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company’s stock valued at $312,491,000 after acquiring an additional 903,683 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in Denali Therapeutics by 7.6% during the 4th quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company’s stock worth $244,993,000 after acquiring an additional 843,996 shares during the period. Institutional investors and hedge funds own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.